Taiji Group (600129.SH): Received Approval Notice for Clinical Trials of Simcereglutide Injection

China Fortune Finance and Economics App news, Taiji Group (600129.SH) announced that its wholly-owned subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd. (referred to as Fuling Pharmaceutical Factory), recently received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for Sumiglutide Injection, allowing the product to conduct clinical trials for the indication of type 2 diabetes.